STOCKHOLM, January 10, 2021. A3P Biomedical strengthens the management team with Marianne Waplan as CFO, Marcela Björn as Director of Marketing & Sales and Malin Gidlund as Head of Lab Operations preparing for the company’s international expansion.
“In order to realize A3P Biomedical’s growth opportunities, we are building a strong organization. I am very proud that Marianne, Marcela and Malin – all with solid experience in their fields – have chosen to join us. We share the vision that Stockholm3 has the potential to revolutionize early detection of prostate cancer. We also share the ambition to build a new exciting company based on world-leading technology that attracts competent employees. Several key people are now in place and we intend to further strengthen the organization during the year.” Martin Steinberg, CEO of A3P Biomedical.
Marianne Waplan, CFO has extensive experience as CFO and management of finance functions. She contributed to the work of listing Hoist Finance on the stock exchange, has been accounting manager at Nordea and SEB and most recently as interim CFO at the private equity company Trill Impact.
Marcela Björn, Director Marketing & Sales has more than 20 years of experience in sales and marketing globally, including as Sales Director for EMEA/Latin America for Vitrolife and management roles within B. Braun Group and Terumo.
Malin Gidlund, Head of Lab Operations, has more than 20 years of experience in Life Science. She most recently came from the role as head of drug development at Orexo and has previously worked with product and process development within Recipharm and AstraZeneca.
For additional information, please contact:
Martin Steinberg, CEO
telephone: +46 709 512068
About A3P Biomedical
A3P Biomedical is a diagnostics company headquartered in Stockholm, Sweden, focusing on prostate cancer. The company’s lead product is Stockholm3, a clinically and commercially validated blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3.
A3P Biomedical’s mission and vision is to radically improve the precision in prostate cancer diagnostics and treatment, thereby significantly reducing mortality and improving the lives of men.
About prostate cancer
Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. In 2020, 1.4 million men are expected to be diagnosed with prostate cancer and 378,000 deaths are expected. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.
Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer. Stockholm3 finds 100 percent more aggressive prostate cancers and reduce 50 percent of unnecessary biopsies compared to current practice with PSA (1).
Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the pivotal study, including 58,000 men, was published in The Lancet Oncology in 2015 (1).
Stockholm3 has not yet applied for national reimbursement in any country. However, based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (with increased sensitivity and specificity) and healthcare providers benefit from direct cost savings of 17 to 28 percent (1).